NanoMaterials Technology ("NMT") has announced that it will conduct a feasibility study with a US based emerging pharmaceutical company.
As part of the feasibility agreement, NMT will apply its proprietary technology, High Gravity Controlled Precipitation (HGCP), to the design of drug particles for pulmonary inhalation.
"Altering the particle design of drug compounds changes the physical properties of the drugs and this leads to enhanced drug efficacy and patient compliance," says Dr Jimmy Yun, the CEO of NMT. NMT's niche in the pharmaceutical industry is in particle design and the company is currently focusing its development on solid oral and inhalation delivery.
NMT is also currently in talks with pharmaceutical companies in the US and Europe for several development agreements. As part of its drive into the pharmaceutical sector, NMT has appointed John Mitchell and Prof. Dr. Siegfried Neumann to its Scientific Advisory Board ("SAB").
"It is a great pleasure and honour for us to have both John and Prof. Neumann joining our SAB. Their addition to our SAB is invaluable as they bring with them broad and in-depth experience in the pharmaceutical industry," says Dr. Yun.